An Emerging Global Leader in the New Generation of Anti-Infective Therapies.
Recce Pharmaceuticals Ltd (ASX: RCE, FSE:R9Q) are pioneering a new class of synthetic anti-infectives to address the urgent global health threat posed by superbugs
Recce’s anti-infectives have been designed with a unique mechanism of action, with the goal of re-empowering physicians with an effective treatment that may be used repeatedly against a broad range of bacteria.
- RECCE® 327 is a fast acting, broad-spectrum antibiotic effective against Gram-positive and Gram-negative bacteria, including antibiotic resistant superbugs.
- RECCE® 435 is a broad-spectrum synthetic polymer antibiotic formulated for oral use.
- RECCE® 529 is a synthetic polymer anti-infective focused on viral indications following Recce’s background antiviral research.
The US Food and Drug Administration (FDA) awarded RECCE® 327 a Qualified Infectious Disease Product (QIDP) designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling RECCE® 327 for Fast Track designation, plus 10 years of market exclusivity post approval.
Origin of
Recce Pharmaceuticals
Recce (pronounced Re-Key) originates from the military term ‘Reconnaissance’ as a military tactic – ‘the aggressive assessment of the disposition of the enemy’. In other words, get troops behind enemy lines, identify the enemy, eliminate the threat, and escape without being noticed.
We have adopted this approach to anti-infectives, where they are designed to:
- Enter the human body;
- Find the infection and threat (deadly bacteria and viruses);
- Eliminate the threat; and
- Exit without being noticed (side effects)
Dr Graham Melrose
Recce Pharmaceuticals was founded by Dr Graham Melrose, a former Executive Director and Head of Research at Johnson & Johnson Asia Pacific and Australia. Building upon his early, independent research, Recce Pharmaceuticals was formed.
Our
Visions and Values
“To address the global health threat of antimicrobial-resistance with a revolutionary portfolio of synthetic anti-infectives.”
Discover
New synthetic polymer-based drugs uniquely designed for targeting major human health threats.
Patent
With over 40 granted patents and patent applications across four families, Recce is well positioned to continue expanding its wholly owned international patent portfolio.
Commercialise
As an Australian Stock Exchange (ASX:RCE) listed company, Recce Pharmaceuticals Ltd is well funded to pursue its drug development activities with a particular focus on the United States of America. Recce’s capitalistic culture sees all technical endeavours focused on a commercial outcome.